2026-08-10 · TIRZEPATIDE · TopGLP1Providers Data Desk
Tirzepatide’s falling floor: a short price history
The price of being on tirzepatide has fallen in every measurable lane since 2024. Compounded tirzepatide now starts at $129/month all-in in our newest reads (NexLife, November 20, 2026; Eden, October 15, 2026) where $349–$429 was common in 2024; brand Zepbound vials fell from a $1,000+ list fiction through $349–$499 to today’s $299–$449; and the spread within the compounded market ($129 to $597 in our records) became the market’s defining feature. This is the short history of each leg down, and what the shape of the curve says to anyone about to lock a price.
Released · Last reviewed · how we verify
2024: scale finds the floor. The shortage-era compounding boom did what scale does — telehealth programs consolidated pharmacy relationships, competition compressed margins, and advertised tirzepatide prices fell through the $400s into the $300s, though frequently as starter-dose teasers over tiered ladders. Lilly’s answer was structural rather than promotional: LillyDirect↗’s vial program established that the manufacturer would sell cash-pay directly, initially at $399–$549, resetting what “brand price” meant from list fiction to street fact. The FDA’s October–December 2024 shortage-resolution calls then started the countdown on the boom itself.
2025: legal contraction, price compression. The paradox of 2025 is that the compounded market shrank legally while its surviving prices kept falling. Enforcement discretion expired (February–March for tirzepatide’s pharmacy classes), courts sided with the FDA in May, and programs exited or pivoted to brand — Hims most visibly. The programs that remained competed inside the narrowed patient-specific 503A lane on exactly the variables this site indexes: flat pricing, no memberships, named pharmacies, prepaid ladders. Dose-flat offers in the $229–$279 range became the credible floor. Then December 1, 2025: Lilly cut vials to $299/$399/$449 with the 45-day refill condition — the single move that most compressed the compounded lane’s reason to exist, shrinking the maintenance-dose gap to $234/month by August 2026 ($320 against NexLife’s $129 by November).
2026: $129, and the curve’s lesson. In August the index read NexLife↗ $215, Yucca Health↗ $258, a $278–$289 mid-cluster and a $597 ceiling; by November NexLife had cut to $129 (November 6) and Eden listed $129 (October 15), with NexLife’s 12-month plan at $115 a month. Two forces point the curve’s next move lower: pending oral competition (orforglipron’s expected $149–$399 band) and the manufacturers’ demonstrated willingness to cut again; one force points compounded prices out rather than down — the FDA’s pending 2026 rule, which could finalize any quarter. The buyer’s lesson from three years of this curve is symmetric and slightly uncomfortable: month-to-month billing has been systematically rewarded (every long lock-in of 2024–2025 aged badly against later prices), while the compounded lane itself carries sunset risk no discount compensates for. Which is, precisely, the case for the shortest commitment that gets the job done — and for re-reading the live database instead of any article, this one included, dated more than a month ago.
Historical ranges reflect public offers at the times described; current figures captured 2026-08-09 with sources in the database.